IPO News Archive

Clovis Oncology files for a $150 million IPO

6/23/11


Clovis Oncology, Inc., a biopharmaceutical company focused on commercializing anti-cancer agents, filed on Thursday with the SEC to raise up to $150 million in an initial public offering. The Boulder, CO-based company, which was founded in 2009, plans to list on the NASDAQ under the symbol CLVS. J.P. Morgan and Credit Suisse are the lead underwriters on the deal. No pricing terms were disclosed.

Keywords/Tickers: CLVS
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest